BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 9193366)

  • 41. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
    Solal-Celigny P; Lepage E; Brousse N; Reyes F; Haioun C; Leporrier M; Peuchmaur M; Bosly A; Parlier Y; Brice P
    N Engl J Med; 1993 Nov; 329(22):1608-14. PubMed ID: 8232429
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.
    Morel P; Gaulard P; Gisselbrecht C; Ferme C; Salles G; Tilly H; Brière J; Copin MC; Lederlin P; Hermine O; Theate I; Haioun C; Mounier N;
    Ann Oncol; 2008 Mar; 19(3):560-5. PubMed ID: 18096567
    [TBL] [Abstract][Full Text] [Related]  

  • 43. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
    Ann Oncol; 2004 Dec; 15(12):1790-7. PubMed ID: 15550584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma.
    Sohn SK; Jung JT; Kim DH; Kim JG; Kwak EK; Park Ti; Shin DG; Sohn KR; Lee KB
    Am J Hematol; 2003 Jun; 73(2):101-7. PubMed ID: 12749011
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical significance in detection of immunoglobulin heavy chain clonal rearrangement in bone marrow of patients with B cell lymphoma].
    Chen ZY; Zhou XY; Zhang TM; Hong XN; Yin JL; Hu XC; Shi DR
    Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):183-8. PubMed ID: 19615255
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group.
    Anderson JR; Vose JM; Bierman PJ; Weisenberger DD; Sanger WG; Pierson J; Bast M; Armitage JO
    J Clin Oncol; 1993 Feb; 11(2):218-24. PubMed ID: 8426197
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
    Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
    J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Follicular large-cell lymphoma: intermediate or low grade?
    Bartlett NL; Rizeq M; Dorfman RF; Halpern J; Horning SJ
    J Clin Oncol; 1994 Jul; 12(7):1349-57. PubMed ID: 8021725
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial.
    Vitolo U; Liberati AM; Cabras MG; Federico M; Angelucci E; Baldini L; Boccomini C; Brugiatelli M; Calvi R; Ciccone G; Genua A; Deliliers GL; Levis A; Parvis G; Pavone E; Salvi F; Sborgia M; Gallo E;
    Haematologica; 2005 Jun; 90(6):793-801. PubMed ID: 15951292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.
    Solal-Céligny P; Lepage E; Brousse N; Tendler CL; Brice P; Haïoun C; Gabarre J; Pignon B; Tertian G; Bouabdallah R; Rossi JF; Doyen C; Coiffier B
    J Clin Oncol; 1998 Jul; 16(7):2332-8. PubMed ID: 9667247
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.
    Bastion Y; Blay JY; Divine M; Brice P; Bordessoule D; Sebban C; Blanc M; Tilly H; Lederlin P; Deconinck E; Salles B; Dumontet C; Brière J; Coiffier B
    J Clin Oncol; 1997 Aug; 15(8):2945-53. PubMed ID: 9256139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin.
    López-Guillermo A; Colomo L; Jiménez M; Bosch F; Villamor N; Arenillas L; Muntañola A; Montoto S; Giné E; Colomer D; Beà S; Campo E; Montserrat E
    J Clin Oncol; 2005 Apr; 23(12):2797-804. PubMed ID: 15728226
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Huang JJ; Zhu YJ; Lin TY; Jiang WQ; Huang HQ; Li ZM
    Hum Pathol; 2011 Oct; 42(10):1459-66. PubMed ID: 21450329
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy.
    Lim ST; Karim R; Nathwani BN; Tulpule A; Espina B; Levine AM
    J Clin Oncol; 2005 Jul; 23(19):4430-8. PubMed ID: 15883411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
    Vitolo U; Cortellazzo S; Liberati AM; Freilone R; Falda M; Bertini M; Botto B; Cinieri S; Levis A; Locatelli F; Lovisone E; Marmont F; Pizzuti M; Rossi A; Viero P; Barbui T; Grignani F; Resegotti L
    J Clin Oncol; 1997 Feb; 15(2):491-8. PubMed ID: 9053470
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
    Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.